Self-injections are emerging as an attractive option for administering drug therapies at home. For instance, insulin-dependent diabetics and individuals suffering from arthritis generally adopt self-inject medication as it is an easy and a reliable method to self-administer drugs.
“Early Buyers Will Receive 20% Customization on This Report.”
The global self-injections market is expected to witness significant growth during the forecast period due to the increasing incidence of auto-immune and chronic disease, and development of biologic drugs to treat autoimmune disease for which auto-injectors (a type of self-injection) are considered the best way of delivery. However, high cost and sterility of injections hamper the market growth.
The self-injection market is segmented based on type, dosage form, therapeutic application, route of administration, end-user, distribution channel, and region. Based on type, market is segmented into devices and formulations. Based on dosage form the self- injections market is segmented into single dose and multi-dose. Based on therapeutic application, the market is segmented into autoimmune diseases, hormonal disorders, oncology, orphan diseases, pain management, respiratory therapy, and others. Based on route of administration, the market is divided into skin, circulatory/musculoskeletal, organs, central nervous system. Considering the distribution channel, the market is divided into hospital pharmacies, private clinics, chemists, and online pharmacies. Based on end-user, the market is segmented into patient, physicians, home care settings, and others. The market is analyzed based on four geographical regions, which include North America, Europe, Asia-Pacific, and LAMEA.
The key players operating in this market include Abbvie, Inc., Antares Pharma, Becton Dickinson & Company, 3M Company, Baxter International Inc., Pfizer Inc., Penjet Corporation, PharmaJet, and Terumo Corporation.
Send Enquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/2017